Plasma Protein Therapeutics Market Update 2023: Anticipated to Attain USD 44.3 Billion Revenue by 2031, Report

The global plasma protein therapeutics market size was valued at $26.5 billion in 2021, and is projected to reach $44.3 billion by 2031, growing at a CAGR of 5.2% from 2022 to 2031.

Request Report Sample Coy PDF Here- https://www.alliedmarketresearch.com/request-sample/13057

Recent Product Launch In the Plasma Protein Therapeutics Market

•    In May 2020, Bio Products Laboratory (BPL) announced that the US launch of ALBUMINEX 5% (human albumin) solution for injection and ALBUMINEX 25% (human albumin) solution for injection., .
•    In September 2021, Grifols announced that TAVLESSE (fostamatinib), used to treat chronic immune thrombocytopenia (ITP) in adult patients refractory to other treatments, is available in France, Italy and Spain and reimbursable from their respective health systems.

Recent Product Development In the Plasma Protein Therapeutics Market

•    In December 2022, Biotest AG announced that, the first of 20 patients has been enrolled in a clinical phase II pilot study for the treatment of chronic hepatitis B with hyperimmunoglobulins at the Hanover Medical School.

•    In June 2022, Biotest AG announced that the planned interim analysis of the phase III AdFIrst (Adjusted Fibrinogen Replacement Strategy) trial with Fibrinogen in patients with acquired fibrinogen deficiency was successful.

•    In May 2020, Biotest AG announced the completion of the clinical trial 984. In the phase I/III study, patients with congenital fibrinogen deficiency were treated with the fibrinogen concentrate (BT524) developed by Biotest in the case of acute bleeding or as prophylactic treatment before surgery.

•    In July 2022, Takeda announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase 3 clinical trial evaluating HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), met its primary endpoint.

Procure Complete Report (262+ Pages PDF with Insights, Charts, Tables, and Figures: https://www.alliedmarketresearch.com/plasma-protein-therapeutics-market/purchase-options

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the plasma protein therapeutics market analysis from 2021 to 2031 to identify the prevailing plasma protein therapeutics industry opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the plasma protein therapeutics market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global plasma protein therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key findings of the study  

• By product type, the immunoglobulin segment was highest contributor to the plasma protein therapeutics industry in 2021 with highest CAGR during the forecast period.
• By application, the hemophilia segment dominated the plasma protein therapeutics industry in 2021. However, primary immunodeficiency is anticipated to grow at highest CAGR during the forecast period.
• On the basis of end user, the hospital segment was dominated the market in 2021. However, others segment is anticipated to grow at the highest CAGR of 5.6 % during the forecast period
• Region wise, North America generated the largest revenue in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR of 6.0 % during the forecast period.

Do Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/13057

Plasma Protein Therapeutics Market Players

• ADMA Biologics Inc
• Baxter Inc
• Bayer AG
• Bio products laboratory
• Baxter International
• Grifsols
• Kedrion SpA
• Octapharma USA Inc

Trending Reports in Healthcare Industry-

Mitral Valve Disease Market https://www.alliedmarketresearch.com/mitral-valve-disease-market-A74388

Surgical Dressing Market https://www.alliedmarketresearch.com/surgical-dressing-market-A74410

Skin Antiseptic Market https://www.alliedmarketresearch.com/skin-antiseptic-market-A12682

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬 –

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.